MAA
AVDL

Managed Account Advisors’s Avadel Pharmaceuticals AVDL Stock Holding History

Managed Account Advisors’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		$1K Buy
+47
New +$843 ﹤0.01% 2992

Other funds holding AVDL

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Managed Account Advisors's AVDL Position: Q2 2015 in Review

Managed Account Advisors opened a new position in Avadel Pharmaceuticals (AVDL) in Q2 2015: 47 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #2992 among its holdings.

87 funds tracked by Wall St. Rank hold AVDL as of Q2 2015.

  • Managed Account Advisors held 47 shares of Avadel Pharmaceuticals worth $1K as of Q2 2015.
  • Avadel Pharmaceuticals was a new Managed Account Advisors position in Q2 2015.
  • Avadel Pharmaceuticals made up ﹤0.01% of Managed Account Advisors's portfolio in Q2 2015, its #2992 holding.
  • 87 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2015.

Based on Managed Account Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.